Opportunity
Simpler Grants.gov #PAR-25-111
NIH Grant for Translational Research in Maternal and Pediatric Pharmacology and Therapeutics
Buyer
National Institutes of Health
Posted
November 18, 2024
Respond By
May 07, 2026
Identifier
PAR-25-111
NAICS
541715
This opportunity from the National Institutes of Health (NIH) seeks grant applications for translational and clinical research to advance precision medicine for pregnant women, lactating women, fetuses, neonates, and children. - Government Buyer: - National Institutes of Health (NIH) - Scope of Research: - Support for projects developing novel tools, models, and technologies with direct clinical or health impact - Emphasis on understanding drug action mechanisms, pediatric ontogeny, and physiological changes during pregnancy and lactation - Promotion of discovery or improvement of therapeutics for safer and more effective medications in maternal and pediatric populations - Funding Instrument: - Grant (not a contract for products or services) - Eligibility: - Open to government entities, educational institutions, businesses, nonprofits, and certain foreign organizations - Products/Services Requested: - No specific OEMs, vendors, products, or part numbers are specified - Unique Requirements: - Research must focus on translational or clinical impact in maternal and pediatric pharmacology and therapeutics - Projects should align with advancing precision medicine and improving drug safety/effectiveness for the target populations
Description
This funding opportunity supports translational and clinical research aimed at advancing precision medicine for pregnant women, lactating women, and children. The research focuses on developing novel tools, models, and technologies with direct clinical impact, understanding drug action mechanisms including pediatric ontogeny and physiological changes during pregnancy and lactation, and discovering or enhancing therapeutics for safer and more effective medications in these populations. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating women, fetuses, neonates, and children, including those with disabilities.